QIAGEN acquire OmicSoft Corporation
QIAGEN announced the acquisition of OmicSoft Corporation, providing access to OmicSoft’s powerful multi-omics data management infrastructure solution as well as ‘omics’ data sets that complement QIAGEN’s bioinformatics portfolio.
OmicSoft is recognized for its suite of software solutions that enable scientists and researchers to efficiently analyse and visualize their own data sets and compare them to massive volumes of publicly available ‘omics’ data sets and share results with colleagues. These solutions, which integrate enterprise access and cloud-based resources, are essential in addressing the rapidly growing need of researchers in discovery and translational research to manage, compare and share the massive volumes of data on DNA, RNA and other biological variables generated with next-generation sequencing (NGS) technologies.
OmicSoft is expected to enhance QIAGEN’s bioinformatics portfolio by adding key features for the management, analysis and sharing of both primary data and analyzed results, while also expanding the range of QIAGEN’s translational and clinical applications.
Through the addition of OmicSoft, QIAGEN will now offer solutions across the full spectrum of data management and interpretation needs. Within these infrastructure solutions, OmicSoft adds the ability to mine curated ‘omics’ data for unpublished findings.
Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE